Background: A high prevalence of hyperandrogenism has been reported in women with type 1 diabetes (T1D). Metformin has been used as a therapeutic agent in patients with polycystic ovarian syndrome and in T1D patients without hyperandrogenism. This study sought to determine the effect of metformin on hyperandrogenism and ovarian function in adolescents with T1D. Methods: We recruited 24 girls with T1D. The participants had hyperandrogenism and displayed suboptimal metabolic control. The patients were enrolled in a randomized, double-blind, placebo-controlled trial. One group received metformin (850 mg bid) and the other group received a placebo. Treatment was administered for 9 months. Ovulation, steroids and gonadotropin levels were evaluated. Results: Metformin treatment was associated with decreases in testosterone, free androgen index, androstenedione, 17-OH progesterone and estradiol levels. The girls who were treated with placebo showed stable steroid, gonadotropin and sex hormone-binding globulin levels during the analysis. No differences were observed in the Ferriman-Gallwey scores, ovulation rates, HbA1c levels or daily insulin doses of the girls treated with metformin compared with the placebo group. Conclusion: Treating hyperandrogenic T1D adolescents with metformin significantly decreased the serum androgens compared to the placebo, but metformin therapy did not significantly affect clinical parameters, such as hirsutism, ovulation and metabolic control.

Djursing H, Hagen C, Nyboe Andersen A, Svenstrup B, Bennett P, Molsted Pedersen L: Serum sex hormone concentrations in insulin dependent diabetic women with and without amenorrhoea. Clin Endocrinol (Oxf) 1985;23:147-154.
Escobar-Morreale HF, Roldan B, Barrio R, Alonso M, Sancho J, de la Calle H, Garcia-Robles R: High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2000;85:4182-4187.
Codner E, Soto N, Lopez P, Trejo L, Avila A, Eyzaguirre FC, Iniguez G, Cassorla F: Diagnostic criteria for polycystic ovary syndrome and ovarian morphology in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2006;91:2250-2256.
Bizzarri C, Benevento D, Rava L, Patera IP, Schiaffini R, Ciampalini P, Giannone G, Cappa M: Ovarian hyperandrogenism in adolescents and young women with type 1 diabetes is primarily related to birth weight and body mass index. Fertil Steril 2011;96:1497-1502. e1491.
Samara-Boustani D, Colmenares A, Elie C, Dabbas M, Beltrand J, Caron V, Ricour C, Jacquin P, Tubiana-Rufi N, Levy-Marchal C, Delcroix C, Martin D, Benadjaoud L, Jacqz Aigrain E, Trivin C, Laborde K, Thibaud E, Robert JJ, Polak M: High prevalence of hirsutism and menstrual disorders in obese adolescent girls and adolescent girls with type 1 diabetes mellitus despite different hormonal profiles. Eur J Endocrinol 2012;166:307-316.
Codner E, Iniguez G, Villarroel C, Lopez P, Soto N, Sir-Petermann T, Cassorla F, Rey RA: Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. J Clin Endocrinol Metab 2007;92:4742-4746.
Codner E, Escobar-Morreale HF: Clinical review: Hyperandrogenism and polycystic ovary syndrome in women with type 1 diabetes mellitus. J Clin Endocrinol Metab 2007;92:1209-1216.
Codner E, Merino PM, Tena-Sempere M: Female reproduction and type 1 diabetes: from mechanisms to clinical findings. Hum Reprod Update 2012;18:568-585.
O'Hare JA, Eichold BH 2nd, Vignati L: Hypogonadotropic secondary amenorrhea in diabetes: effects of central opiate blockade and improved metabolic control. Am J Med 1987;83:1080-1084.
Roldan B, Escobar-Morreale HF, Barrio R, de La Calle H, Alonso M, Garcia-Robles R, Sancho J: Identification of the source of androgen excess in hyperandrogenic type 1 diabetic patients. Diabetes Care 2001;24:1297-1299.
Codner E, Mook-Kanamori D, Bazaes RA, Unanue N, Sovino H, Ugarte F, Avila A, Iniguez G, Cassorla F: Ovarian function during puberty in girls with type 1 diabetes mellitus: response to leuprolide. J Clin Endocrinol Metab 2005;90:3939-3945.
Ibanez L, Valls C, Potau N, Marcos MV, de Zegher F: Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche. J Clin Endocrinol Metab 2000;85:3526-3530.
Arslanian SA, Lewy V, Danadian K, Saad R: Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. J Clin Endocrinol Metab 2002;87:1555-1559.
Nestler JE, Jakubowicz DJ: Decreases in ovarian cytochrome p450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335:617-623.
Palomba S, Falbo A, Zullo F, Orio F Jr: Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev 2009;30:1-50.
Yki-Jarvinen H, Koivisto VA: Continuous subcutaneous insulin infusion therapy decreases insulin resistance in type 1 diabetes. J Clin Endocrinol Metab 1984;58:659-666.
Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D: Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance: a randomized controlled trial. Diabetes Care 2003;26:138-143.
Sarnblad S, Kroon M, Aman J: Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomised placebo-controlled trial with aspects on insulin sensitivity. Eur J Endocrinol 2003;149:323-329.
Tellez R, Frenkel J: Clinical evaluation of body hair in healthy women. Rev Med Chil 1995;123:1349-1354.
Lottrup G, Jorgensen A, Nielsen JE, Jorgensen N, Duno M, Vinggaard AM, Skakkebaek NE, Rajpert-De Meyts E: Identification of a novel androgen receptor mutation in a family with multiple components compatible with the testicular dysgenesis syndrome. J Clin Endocrinol Metab 2013;98:2223-2229.
Barbesino G, Tomer Y: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013;98:2247-2255.
Ibanez L, Potau N, Ferrer A, Rodriguez-Hierro F, Marcos MV, De Zegher F: Anovulation in eumenorrheic, non-obese adolescent girls born small for gestational age: insulin sensitization induces ovulation, increases lean body mass, and reduces abdominal fat excess, dyslipidemia, and subclinical hyperandrogenism. J Clin Endocrinol Metab 2002;87:5702-5705.
Ladson G, Dodson WC, Sweet SD, Archibong AE, Kunselman AR, Demers LM, Lee PA, Williams NI, Coney P, Legro RS: Effects of metformin in adolescents with polycystic ovary syndrome undertaking lifestyle therapy: a pilot randomized double-blind study. Fertil Steril 2011;95:2595-2598.e1-e6.
Mansfield R, Galea R, Brincat M, Hole D, Mason H: Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril 2003;79:956-962.
Attia GR, Rainey WE, Carr BR: Metformin directly inhibits androgen production in human thecal cells. Fertil Steril 2001;76:517-524.
Sonntag B, Gotte M, Wulfing P, Schuring AN, Kiesel L, Greb RR: Metformin alters insulin signaling and viability of human granulosa cells. Fertil Steril 2005;84(suppl 2):1173-1179.
Warren-Ulanch J, Arslanian S: Treatment of PCOS in adolescence. Best Pract Res Clin Endocrinol Metab 2006;20:311-330.
Catteau-Jonard S, Cortet-Rudelli C, Richard-Proust C, Dewailly D: Hyperandrogenism in adolescent girls. Endocr Dev 2012;22:181-193.
Pfeifer SM, Kives S: Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am 2009;36:129-152.
Loriaux DL: An approach to the patient with hirsutism. J Clin Endocrinol Metab 2012;97:2957-2968.
Codner E, Eyzaguirre FC, Iniguez G, Lopez P, Perez-Bravo F, Torrealba IM, Cassorla F, Chilean Group for the Study of Ovarian Function in Type D: Ovulation rate in adolescents with type 1 diabetes mellitus. Fertil Steril 2011;95:197-202.e191.
Ibanez L, Valls C, Ferrer A, Marcos MV, Rodriguez-Hierro F, de Zegher F: Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 2001;86:3595-3598.
Heard MJ, Pierce A, Carson SA, Buster JE: Pregnancies following use of metformin for ovulation induction in patients with polycystic ovary syndrome. Fertil Steril 2002;77:669-673.
Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER, the Cooperative Multicenter Reproductive Medicine Network: Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007;356:551-566.
Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R: Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338:1876-1880.
Abdelghaffar S, Attia AM: Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents. Cochrane Database Syst Rev 2009;1:CD006691.
Urakami T, Morimoto S, Owada M, Harada K: Usefulness of the addition of metformin to insulin in pediatric patients with type 1 diabetes mellitus. Pediatr Int 2005;47:430-433.
Gomez R, Mokhashi MH, Rao J, Vargas A, Compton T, McCarter R, Chalew SA: Metformin adjunctive therapy with insulin improves glycemic control in patients with type 1 diabetes mellitus: a pilot study. J Pediatr Endocrinol Metab 2002;15:1147-1151.
Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, Guerci B: The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002;25:2153-2158.
Jacobsen IB, Henriksen JE, Beck-Nielsen H: The effect of metformin in overweight patients with type 1 diabetes and poor metabolic control. Basic Clin Pharmacol Toxicol 2009;105:145-149.
Khan AS, McLoughney CR, Ahmed AB: The effect of metformin on blood glucose control in overweight patients with type 1 diabetes. Diabet Med 2006;23:1079-1084.
Daniel JR, Hagmeyer KO: Metformin and insulin: Is there a role for combination therapy? Ann Pharmacother 1997;31:474-480.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.